Leyla Weighs In: Conquering Insulin Resistance–The Future of PMOS Treatment

PCOS Renamed PMOS, and a Low-Calorie Diet/Exercise Trial for Type 2 Diabetes Remission: Nutritionist Leyla Muedin discusses polycystic ovarian syndrome being renamed polyendocrine metabolic ovarian syndrome (PMOS), emphasizing insulin resistance as a primary driver and noting PMOS affects an estimated 10–13% of reproductive-age women worldwide with an $8B U.S. economic burden. She reviews symptoms and comorbidities (irregular menses, hirsutism, infertility, hypertension, type 2 diabetes, depression/anxiety, sleep apnea, adverse lipids, increased cerebrovascular risk) and says variable presentations can delay diagnosis and leave patients dissatisfied with mainstream care focused on birth control, spironolactone, and metformin with little diet counseling. She highlights functional medicine and lifestyle interventions (diet, nutraceuticals, exercise, mind-body therapies), citing evidence for improved androgens, weight/BMI, mental health, and notes adjunct promise for acupuncture. She then summarizes a trial where an 800–900 kcal/day diet plus supervised exercise achieved 54% remission in early-onset type 2 diabetes vs 4% with usual care, but argues it’s unsustainable and suggests low-carb approaches.